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Abstract
OBJECTIVES: Data on the impact and course of uncorrected tricuspid regurgitation (TR) during left ventricular assist device (LVAD) im-
plantation are scarce and inconsistent. This study explores the clinical impact and natural course of uncorrected TR in patients after LVAD
implantation.
METHODS: The European Registry for Patients with Mechanical Circulatory Support was used to identify adult patients with LVAD
implants without concomitant tricuspid valve surgery. A mediation model was developed to assess the association of TR with 30-day mor-
tality via other risk factors. Generalized mixed models were used to model the course of post-LVAD TR. Joint models were used to perform
sensitivity analyses.
RESULTS: A total of 2496 procedures were included (median age: 56 years; men: 83%). TR was not directly associated with higher 30-day
mortality, but mediation analyses suggested an indirect association via preoperative elevated right atrial pressure and creatinine (P = 0.035)
and bilirubin (P = 0.027) levels. Post-LVAD TR was also associated with increased late mortality [hazard ratio 1.16 (1.06–1.3); P = 0.001].
On average, uncorrected TR diminished after LVAD implantation. The probability of having moderate-to-severe TR immediately after
an implant in patients with none-to-mild TR pre-LVAD was 10%; in patients with moderate-to-severe TR pre-LVAD, it was 35% and contin-
ued to decrease in patients with moderate-to-severe TR pre-LVAD, regardless of pre-LVAD right ventricular failure or pulmonary
hypertension.
CONCLUSIONS: Uncorrected TR pre-LVAD and post-LVAD is associated with increased early and late mortality. Nevertheless, on average,
TR diminishes progressively without intervention after an LVAD implant. Therefore, these data suggest that patient selection for concomi-
tant tricuspid valve surgery should not be based solely on TR grade.
Keywords: Left ventricular assist device • Tricuspid regurgitation • Mortality • Natural course
ABBREVIATIONS
CI Confidence interval
EUROMACS European Registry for Patients with
Mechanical Circulatory Support
LVAD Left ventricular assist device
RA Right atrium
RV Right ventricular
RVF Right ventricular function
SEM Structural equation model
TR Tricuspid regurgitation
INTRODUCTION
Tricuspid regurgitation (TR) is common in patients with end-stage
heart failure undergoing left ventricular assist device (LVAD) im-
plant [1]. Most studies addressing TR after an LVAD implant focus
on comparing patients with and without tricuspid valve surgery
concomitant with an LVAD implant [2]. However, it is still unclear
what the ‘natural’ course of post-LVAD TR is, and which patients
will potentially benefit most from concomitant tricuspid valve sur-
gery. TR has been reported to decrease after an LVAD implant [3–
5], but it is not known whether this occurs in all patients uniformly
or only in subgroups. Assessing the course and clinical impact of
TR after LVAD is important, because it may provide a rationale to
perform, or to refrain from performing, tricuspid valve surgery
during LVAD implantation. Therefore, this study explores the evo-
lution of TR after an LVAD implant in patients who did not under-
go concomitant tricuspid valve surgery. Furthermore, we explored
the impact of the preoperative and postoperative TR grade on
early (30-day) and late mortality using the European Registry for
Patients with Mechanical Circulatory Support (EUROMACS) data-
base. We hypothesized that pre-LVAD TR is part of an interplay
with other risk factors [e.g. right ventricular (RV) failure, pulmon-
ary hypertension, renal and/or liver function] and that TR may be
associated with 30-day mortality by increasing these risk factors.
Therefore, we performed a mediation analysis. To account for the
dynamic nature of TR after LVAD implantation and potential sur-
vival bias, the longitudinal evolution of TR was modelled and
linked to survival under the joint modelling framework.
METHODS
Data source
EUROMACS is a registry of the European Association for Cardio-
Thoracic Surgery. In this registry, all relevant clinical, echocardio-
graphic haemodynamic and laboratory parameters of patients
who require mechanical circulatory support have been collected
prospectively since January 2011. Participating centres
(Supplementary Material, Table S1) were allowed to enter data
before 2011 retrospectively. Detailed descriptions of the database
and collection procedure were provided previously [6].
Patients
All patients operated between 2005 and 2018 were identified.
Patients under 18 years of age, with no recorded pre-LVAD TR
grade and with concomitant tricuspid valve surgery were
excluded from analysis (Supplementary Material, Fig. S1).
Additionally, we excluded patients with a planned durable RV as-
sist device, biventricular assist device or total artificial heart im-
plant. Patients were followed until death or the end of the study.
Patients were censored at heart transplant or explant.
Outcome
The main outcomes that were assessed were 30-day mortality,
late mortality (defined as death after 30 days) and TR grade (5-
point system: none–trivial–mild–moderate–severe).
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Statistical analyses
Continuous data are presented as mean (standard deviation)
(Gaussian distribution) or median (interquartile range) (non-
Gaussian distribution). Categorical data are presented as frequen-
cies (percentage). Comparisons among continuous variables were
made with the one-way analysis of variance or the Kruskal–Wallis
test, as appropriate. Continuous data outside 3 standard devia-
tions were considered erroneous and removed (Supplementary
Material, Table S2). Comparisons of categorical variables were
made with the v2 test or with the Fisher’s exact test, as appropri-
ate. Due to multiple testing (34 tests), a Bonferroni correction
was applied, considering P = 0.0014 as significantly different. Data
with <50% missing values were imputed using multiple imput-
ation (Supplementary Material, Text S1 and Tables S3 and S4).
Univariable and multivariable ordinal proportional odds re-
gression models were used to explore determinants associated
with TR at baseline. A forwards stepwise modelling strategy was
applied in which all covariates with P-value <0.10 were entered
into the multivariable model.
We hypothesized that the effect of TR on 30-day mortality was
mediated by well-known risk factors. Therefore, mediation analysis
with a structural equation model (SEM) was performed. The
selected variables incorporated into the model included right atrial
pressure, creatinine and bilirubin levels and the international nor-
malized ratio (all were incorporated as continuous variables), and
were based on previous literature [7–9]. Using SEM, one can com-
pute direct and indirect associations (associations via other varia-
bles) on outcomes by specifying a pathway. The conceptual
pathways are shown in Fig. 1. A comprehensive explanation of me-
diation analyses with SEM is provided in Supplementary Material,
Text S1. Late mortality was calculated and visualized using the
Kaplan–Meier method, and a log-rank test was performed to com-
pare strata. Modified Clark’s C, denoted as C*, was used to calculate
completeness of follow-up [10].
Evolution of tricuspid regurgitation
Logistic mixed models were used to assess longitudinal evolution
of TR grade over time (Supplementary Material, Text S1).
Subgroup analysis was done for patients with moderate-to-
severe TR pre-LVAD. In these patients, separate models contain-
ing RV ejection fraction impairment, pulmonary hypertension,
pre-LVAD mitral regurgitation, pre-LVAD rhythm, duration of
cardiac diagnosis (time elapsed since first cardiac diagnosis) and
pre-LVAD right atrium (RA) pressure were developed to investi-
gate the association of these variables with the course of post-
LVAD TR. All analyses were done in R (version 3.6.3) (R Project
for Statistical Computing: https://www.r-project.org/).
Sensitivity analyses
It is possible that a portion of the dropout of patients is
caused by deaths due to TR, resulting in informative censor-
ing (survival bias). In this case, the dropout is not random,
thus leading to bias in the mixed model results. Therefore, a
sensitivity analysis was performed in which the dynamic lon-
gitudinal evolution of TR was inserted into a Cox model under
the joint modelling framework. Modelling these entities to-
gether alleviates possible bias due to missing values that are
missing not at random (i.e. survival bias). The other baseline
covariates inserted in the Cox model were based on informa-
tion from previously published articles; only the current value
parameterization of TR was investigated [11, 12]. Several
other sensitivity analyses were conducted to test the robust-
ness of the model estimates. These analyses included: exclu-
sion of patients with pre-LVAD extracorporeal membrane
oxygenation and patients with postoperative durable RV as-
sist device. Additionally, centre heterogeneity was accounted
for in the random effects by performing a mixed model with
patients nested in hospitals.
Figure 1: Path diagram of the structural equation model with table of regressions. Paths are indicated by labels a–h, which correspond to the labels in Table 3. Arrows
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RESULTS
The database contained 3948 procedures. After applying the exclu-
sion criteria, 2411 patients undergoing 2496 procedures were
included (Supplementary Material, Fig. S1). In total, 1892 patients
had recorded late follow-up (>30 days) with a median of 1.3 inter-
quartile range (0.5–2.6) years, with a completeness of 85% (C*).
Baseline characteristics
Baseline characteristics stratified to TR grade are presented in
Table 1. Nearly all the baseline characteristics differed significant-
ly between patients with none-to-mild TR compared to those
with moderate-to-severe TR, even after the Bonferroni
correction. Seventy-three potential determinants were tested in
univariable ordinal regression models, and 12 determinants
remained significant in multivariable analyses. Among others,
a higher TR grade at baseline was significantly associated
with more peripheral oedema, other pulmonary and mitral
valve dysfunction, higher RA pressure, more loop diuretics and
worse right ventricular function (RVF) (Supplementary Material,
Table S5).
Pre-left ventricular device tricuspid regurgitation
and early mortality
In total, 271 (10.9%) patients died within 30 days. The 30-day
mortality was comparable between patients with none-to-mild
Table 1: Baseline characteristics stratified to pre-left ventricular assist device TR grade
None-to-mild TR Moderate-to-severe TR P-value
Demographics
n 1690 806
Age (years) 56.00 (47.00–62.00) 56.00 (46.00–62.00) 0.71
Male gender, n (%) 1416 (83.8) 657 (81.5) 0.17
Body surface area (m2) 1.99 (1.83–2.12) 1.92 (1.78–2.08) <0.001
White race, n (%) 1234 (86.3) 626 (86.2) 0.97
Ischaemic aetiology HF, n (%) 620 (43.3) 251 (35.2) <0.001
>_2 Years since first diagnosis 811 (60.3) 494 (70.4) <0.001
Destination therapy 294 (17.5) 128 (15.9) 0.36
Ascites 96 (8.5) 94 (16.9) <0.001
Rhythm, n (%) 0.001
Sinus 796 (58.1) 341 (49.6)
Atrial fibrillation 225 (16.4) 130 (18.9)
Paced 28 (2.0) 28 (4.1)
Other 322 (23.5) 189 (27.5)
INTERMACS profile, n (%) <0.001
1 238 (14.7) 79 (10.1)
2 538 (33.3) 259 (33.2)
3 457 (28.3) 205 (26.3)
>_4 384 (23.7) 237 (30.4)
IABP, n (%) 173 (12.0) 58 (8.1) 0.008
ECMO, n (%) 183 (11.2) 50 (6.5) <0.001
Ventilator (%) 224 (15.6) 52 (7.3) <0.001
Medication, n (%)
Loop diuretics 1060 (78.8) 588 (86.7) <0.001
Use of >_3 inotropes 182 (13.0) 93 (13.3) 0.91
Laboratory values
Serum creatinine (mg/dl) 106.00 (84.00–146.00) 106.00 (82.00–144.00) 0.43
ASAT (U/l) 33.00 (22.00–70.00) 30.00 (21.00–55.00) 0.002
Total bilirubin (mg/dl) 1.18 (0.74–1.90) 1.40 (0.90–2.27) <0.001
Albumin (g/dl) 499.91 (410.07–579.60) 521.64 (440.50–579.60) 0.010
Haemoglobin (g/dl) 12.00 (10.30–13.60) 11.75 (10.20–13.30) 0.17
Haemodynamics
RA pressure (mmHg) 10.00 (6.00–14.00) 11.00 (8.00–16.00) <0.001
PCWP (mmHg) 24.00 (17.00–30.00) 25.00 (20.00–30.00) 0.005
PAP, systolic (mmHg) 51.00 (38.00–62.00) 53.00 (41.75–65.00) 0.003
Echocardiography
TAPSE (mm) 15.00 (12.00–17.00) 14.00 (11.00–16.00) <0.001
No aortic regurgitation, n (%) 1043 (67.8) 397 (54.8) <0.001
Severe mitral regurgitation, n (%) 162 (11.1) 223 (30.3) <0.001
LVEF grade <20%, n (%) 779 (57.2) 431 (64.2) 0.010
RVF <0.001
Normal 279 (24.4) 89 (15.6)
Mild 334 (29.2) 105 (18.4)
Moderate 389 (34.1) 274 (48.1)
Severe 140 (12.3) 102 (17.9)
Normally distributed variables are presented as means (standard deviations) and not normally distributed variables are medians (interquartile range).
ASAT: aspartate aminotransferase; ECMO: extracorporeal membrane oxygenation; HF: heart failure; IABP: intra-aortic balloon pump; INTERMACS: Interagency
Registry for Mechanically Assisted Circulatory Support; LVEF: left ventricular ejection fraction; PAP: pulmonary atrial pressure; PCWP: pulmonary capillary wedge
pressure; RA: right atrium; RVF: right ventricular function; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation.
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TR versus moderate-to-severe TR (10.8% vs 10.9%; P = 0.99).
Procedural and hospital outcomes in patients with none-to-mild
and moderate-to-severe TR are presented in Table 2.
The conceptual paths of the SEM are shown in Fig. 1 and the
regression estimates and significance, in Table 3. Overall, the
model fitted well, as indicated by the fit indices in Table 3.
Although the total effect of TR on 30-day mortality was
insignificant, the path TR to RA pressure to creatinine was signifi-
cantly associated with 30-day mortality (P = 0.035) (Table 3).
Additionally, the path TR to RA pressure to bilirubin was signifi-
cantly associated with 30-day mortality (P = 0.027) (Table 3).
However, the path TR to RA pressure to international normalized
ratio was not associated with 30-day mortality (P = 0.057)
(Table 3).
Table 2: Procedural characteristics and early outcomes
None-to-mild TR Moderate-to-severe TR P-value
Device 0.005
HeartMate II LVAS 484 (29.5) 186 (24.2)
HeartWare HVAD 841 (51.3) 452 (58.8)
HeartMate3 241 (14.7) 95 (12.4)
Other 74 (4.5) 36 (4.7)
CPB time 79.00 (58.00–108.00) 80.00 (60.00–111.00) 0.22
ICU/CCU stay (days) 10.00 (5.00–23.00) 10.00 (5.00–22.00) 0.81
Hospital stay (days) 29.00 (21.00–43.00) 31.00 (21.00–44.00) 0.18
Discontinuation of IV inotropes (days) (%) 0.30
1–7 558 (55.0) 295 (58.4)
8–13 184 (18.1) 97 (19.2)
14–27 168 (16.6) 73 (14.5)
>27 103 (10.1) 38 (7.5)
Temporary RVAD 66 (3.9) 39 (4.8) 0.32
30-Day mortality, n (%) 184 (10.9) 87 (10.8) >0.99
Normally distributed variables are presented as means (standard deviations) and not normally distributed variables are medians (interquartile ranges).
CCU: coronary care unit; CPB: cardiopulmonary bypass; ICU: intensive care unit; IV: intravenous; LVAS: left ventricular assist system; RVAD: right ventricular assist
device; TR: tricuspid regurgitation.
Table 3: Estimates of the paths of the structural equation model
Regressions Patha b-Estimate (95% CI) P-value
Mortality 
Bilirubin f 0.056 (0.003–0.080) >0.001
Creatinine e 0.001 (0.001–0.001) >0.001
INR g 0.121 (0.033–0.209) 0.007
Age i 0.016 (0.010–0.021) >0.001
TR per 1 grade h -0.047 (-0.101 to 0.007) 0.087
RA pressure 
TR a 0.805 (0.464–1.146) >0.001
Bilirubin 
RA pressure c 0.048 (0.023–0.072) 0.002
Creatinine 
RA pressure b 1.159 (0.341–1.977) 0.015
INR
RA pressure d 0.011 (0.003–0.019) 0.011
Indirect effects of TR
Direct effect h -0.047 (-0.101 to 0.007) 0.087
RA pressure—creatinine a–b–e 0.001 (0.001–0.001) 0.035
RA pressure—bilirubin a–c–f 0.002 (0.001–0.003) 0.027
RA pressure—INR a–d–g 0.001 (0.000–0.001) 0.058
Total effect -0.043 (-0.098 to 0.012) 0.12
Fit measures
v2 >0.001
Non-normed fit index 0.95
Comparative fit index 0.98
Root mean square error of approximation (95% CI) 0.051 (0.037–0.065)
Standardized root mean square residual 0.065
aPaths correspond to the paths specified in Fig. 1.
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Pre-left ventricular assist device tricuspid
regurgitation and late mortality
A total of 626 of 2410 thirty-day survivors died during the long-
term (>30 days) follow-up period. Survival after 30 days, stratified
to none-to-mild TR versus moderate-to-severe TR at baseline, is
presented in Fig. 2 and differed significantly between strata
(P = 0.015).
The Spearman correlation between pre-LVAD TR and pre-
LVAD RVF was 0.22 (P < 0.001). Therefore, these variables were
combined into 1 variable. In Fig. 3 the population is stratified to
different levels of right ventricle dysfunction with or without sig-
nificant TR. Three years after implant, the Kaplan–Meier survival
estimate was lower in patients with both moderate-to-severe TR
and RVF [54%, 95% confidence interval (CI) 47–61] compared to
patients with good RVF and none-to-mild TR (68%, 95% CI 64–
73). In a sensitivity analysis with only complete cases, the group
with both moderate-to-severe TR and RVF pre-LVAD had survival
and hazard ratios comparable to those of patients with none-to-
mild TR and moderate-to-severe RVF pre-LVAD (Supplementary
Figure 2: Kaplan–Meier curve of late survival (includes only 30-day survivors) after LVAD implant stratified to pre-LVAD TR grade. LVAD: left ventricular assist device;
TR: tricuspid regurgitation.
Figure 3: Kaplan–Meier curve of late survival (includes only 30-day survivors) after left ventricular assist device implant stratified to pre-left ventricular assist device TR
grade with or without right ventricular dysfunction. Of note, data from the first imputed data set are used. RVF: right ventricular failure, mod: moderate; sev: severe;
TR: tricuspid regurgitation.
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Material, Figs S2 and S3). RVF did seem to be conditionally
missing based on observed variables (Supplementary Material,
Table S6).
Evolution of tricuspid regurgitation
During the follow-up period, 914 (48%) patients had 1 or more
echocardiograms, with 3113 echocardiograms in total (mean 3.4,
range 1–8) (Supplementary Material, Fig. S4). Figure 4A presents
the probabilities of having moderate-to-severe TR after an LVAD
implant, stratified to pre-LVAD TR severity. The odds of
moderate-to-severe TR after an LVAD implant decreased over
time and became comparable after 1.4 years in patients with
moderate-to-severe TR pre-LVAD versus patients with none-to-
mild TR pre-LVAD.
In patients with moderate-to-severe TR pre-LVAD, no signifi-
cant differences were observed in the course of TR post-LVAD
among different levels of pre-LVAD RV ejection fraction impair-
ment, pre-LVAD pulmonary hypertension, pre-LVAD mitral re-
gurgitation, pre-LVAD rhythm, duration of cardiac diagnoses, an
implantable cardioverter-defibrillator or pre-LVAD RA pressure
(Supplementary Material, Figs S5–S11), except for patients with
idiopathic dilated myopathy. In these patients post-LVAD TR
decreased faster compared to patients with other diagnoses
(Fig. 4B), but the odds of moderate-to-severe TR became com-
parable after 2.5 years. The difference in the odds of moderate-
to-severe TR was observed predominantly in patients with other
diagnoses (e.g. myocarditis and toxic or postpartum myopathy)
compared to patients with idiopathic dilated myopathy (Fig. 4B).
To gain insight into the possibility of informative censoring (sur-
vival bias), the longitudinal evolution of TR was jointly modelled
with a survival model and compared with the estimates of the
mixed model (Supplementary Material, Table S7). Some sensitiv-
ity was observed in both the effect size and standard errors
(Supplementary Material, Table S8); however, the direction of the
effect did not change, nor did the significance. Hence, the de-
crease in the probability of TR after LVAD cannot be solely
explained by survival bias.
Post-left ventricular assist device tricuspid
regurgitation and mortality
Moderate-to-severe TR post-LVAD was associated with
increased mortality (hazard ratio 1.16, 95% CI 1.06–1.30;
P = 0.001), as estimated by the joint model adjusted for several
baseline variables including RV dysfunction (Supplementary
Material, Table S7).
Sensitivity analyses
Sensitivity analyses were performed to test the robustness of
the outcomes. Estimates of the evolution of TR did not change
considerably if patients with pre-LVAD ECMO were excluded
(Supplementary Material, Tables S9 and S10). Including the
centre as a random effect did not change estimates
(Supplementary Material, Table S11). Furthermore, centres that
tended to repair the tricuspid valve in the setting of moderate-
to-severe TR pre-LVAD had similar evolutions of post-LVAD TR
in patients without tricuspid valve intervention compared to
centres that were not inclined to repair the tricuspid valve
(Supplementary Material, Fig. S12). Excluding patients with an
RV assist device implant during the follow-up period did not
Figure 4: (A) Effects plot of the probability of TR after left ventricular assist device (LVAD) implant stratified to pre-LVAD. (B) Effects plot of the evolution of TR after
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considerably change the estimates of the longitudinal evolution
or of survival (Supplementary Material, Tables S12 and S13).
DISCUSSION
This study explores the clinical impact of pre-LVAD and post-
LVAD TR on 30-day and late mortality and the course of post-
LVAD TR in the survivors. Interesting observations were noted:
both pre- and post-LVAD TR seemed to be associated with
reduced survival. Nevertheless, on average, TR resolved ‘spontan-
eously’ after an LVAD implant, which was not solely due to sur-
vival bias.
Early and late mortality
We hypothesized that TR is part of an entire pathway that may
lead to higher 30-day mortality, i.e. mediated by other variables.
To gain insight in this hypothesis, we developed a conceptual
model with several paths (Fig. 1). When this model was tested, it
fit well, suggesting that TR may not be directly related to 30-day
mortality but that by increasing other risk factors it is indirectly
associated with 30-day mortality. Notably, we did not include
RVF in the pathways because of the circular relation with the se-
verity of TR, which cannot be modelled. The impaired RVF can
lead to TR due to RV/annulus dilation, but also the other way
around due to volume or pressure overload [7]. Furthermore, TR
was chosen in the model because TR is associated with renal dys-
function in the literature [9].
The investigators of the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) found TR to be asso-
ciated with reduced late survival [13]. Assessing the Kaplan–Meier
curve of the combined variables, it seems that pre-LVAD-
impaired RVF is the driving factor in late mortality after an LVAD
implant; however, impaired RVF accompanied by TR resulted in
an even worse survival. These data may suggest that pre-LVAD
TR in the setting of impaired RVF adds extra late risk, which can
partly be explained by the negative spiral that ensues when TR is
present in the setting of impaired RVF, leading to more dysfunc-
tion. Furthermore, TR together with impaired RVF is associated
more with renal failure than with isolated TR or impaired RVF
alone [14, 15]. Nevertheless, it has to be noted that confounding
may be present here, and, in a sensitivity analysis with complete
cases, pre-LVAD RVF did seem to be the driving factor regardless
of pre-LVAD TR. RVF was conditionality missing upon other
observed baseline variables, suggesting the missing at random
mechanism. Multiple imputation is more valid in missing-at-
random scenarios [16].
Evolution of tricuspid regurgitation
TR decreases without intervention after an LVAD implant, and
this decrease is not solely based on patients dying of TR. Overall,
an immediate decrease of 65% is observed from moderate-to-
severe TR to non-to-mild TR in patients with moderate-to-severe
TR pre-LVAD. Other studies comparing point estimates over time
noted comparable results [1, 4]. The decrease in TR may be
explained by the fact that LVAD support reduces pulmonary
pressures, subsequently reducing the pressure overload of the
right ventricle, which leads to right ventricle remodelling and
regression of the tricuspid valve annulus dilatation. The remodel-
ling in turn leads to resolution of functional TR.
Furthermore, it seems that TR decreases more quickly in
patients with idiopathic cardiomyopathy compared to other car-
diomyopathies. However, later in the follow-up period, this dif-
ference disappears. Furthermore, these results can be explained
by confounding because the models were univariable, and some
misclassifications in TR grade will be present, which can bias out-
come in the small subgroups.
Clinical implications and rationale for eventual
tricuspid valve surgery
The observations of this study in respect to concomitant tricuspid
valve surgery can be interpreted in 2 ways. First, one can argue
that concomitant surgery of the tricuspid valve is warranted, be-
cause both preoperative and postoperative TR are associated
with increased mortality. It has to be noted that this study by de-
sign cannot establish a causal relationship between TR and mor-
tality, and TR may just be a marker of significant RVF. Second,
one can argue that a less aggressive strategy is warranted be-
cause, on average, the TR will resolve after LVAD implantation
without any further intervention.
Current guidelines advise consideration of tricuspid valve sur-
gery in the presence of moderate or severe TR at baseline.
Current practice notwithstanding, we may be overtreating
patients with unnecessary concomitant tricuspid valve surgery if
we follow the guidelines. This deficit also may explain why previ-
ous studies comparing patients with and without concomitant
tricuspid valve surgery were unable to find an effect [2]. Some
patients will not benefit because TR will resolve without an inter-
vention. Therefore, the key point seems to be appropriate patient
selection, taking into account the aetiology of TR, the severity of
RV dysfunction and the underlying myocardial disease when
deciding to perform concomitant surgery. Anwer et al. [17] pro-
posed that atrial fibrillation should be included in this decision
process. We were not able to show a significant effect of pre-
LVAD atrial fibrillation on the odds of significant TR post-LVAD
with the subgroup analyses, but there were only a few patients in
the atrial fibrillation group. Functional TR has a chance to reduce
spontaneously, whereas primary TR (e.g. caused by a pacemaker
or an implantable cardioverter-defibrillator lead) probably will
not. Furthermore, functional TR has not only been caused by tri-
cuspid valve annular dilatation but also by valve tethering [18]. In
the case of severe tethering, tricuspid annuloplasty may not be
enough to reduce TR [19].
Future perspectives
Future studies should focus on understanding the different mech-
anisms and concomitant factors contributing to significant TR
and finding the appropriate predictors of TR after LVAD implant-
ation, preferably in a longitudinal prospective dedicated data set
encompassing RV functional and dimensional, pulmonary and
haemodynamic parameters. Therefore, we recently set up the
Serial Multiparametric Evaluation of Right Ventricular Function
After Left Ventricular Assist Device Implantation (EuroEchoVAD)
study (see clinicaltrails.org, NCT03552679) to investigate the evo-
lution of RVF, TR and other echocardiographic parameters before
and after LVAD implantation. The findings of the study will en-
hance the prediction of the early and late development of
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postoperative RVF, the course of TR severity and the subsequent
mortality and morbidity. Furthermore, novel transcatheter devi-
ces to treat tricuspid valve regurgitation are on the horizon.
These devices have the potential to become interesting addenda
in the treatment of functional TR in the setting of LVAD implant-
ation. However, several challenges need to be addressed before
they can enter daily clinical practice [20].
Limitations
This study has several limitations common to retrospective regis-
try analyses. EUROMACS is not designed to address the specific
questions in this study. Therefore, there is a limited amount of
data collected with a focus on the right ventricle, or these data
are not uniformly collected. Furthermore, it has to be empha-
sized that misspecification may be present in a registry and that
follow-up is suboptimal, which can introduce bias. We prevented
more loss of data by imputation of the missing data in order to
generate more power in the analysis. Nevertheless, some varia-
bles could not be imputed due to excessive missingness, and we
could not use the longitudinal trajectory of TR in the imputation
model. Additionally, follow-up data on TR were not collected at
prespecified, regular intervals and assessing TR remains challeng-
ing [21]. However, we used mixed models, which can handle
these unstructured data sets, and TR was dichotomized in these
models to create a more robust measurement. Unfortunately, in
some subgroups, the sample size was small, and it was not
known if patients had tricusispid valve surgery during the follow-
up period. Advanced path models are used to shed some light
on the impact of TR on 30-day mortality via other variables.
However, due to the circular relationship with RVF, the true effect
of TR on mortality may be impossible to estimate. Thereafter, the
mechanism of TR was not recorded in the registry. Presumably,
most of the TR is functional in nature, supported by the fact that
TR is associated with RVF and its symptoms/treatment.
CONCLUSIONS
Moderate-to-severe TR pre-LVAD is positively correlated with
worse RVF pre-LVAD and is associated with worse late mortality.
However, overall, TR decreases after the LVAD is implanted, re-
gardless of pre-LVAD pulmonary hypertension or right ventricle
function. Hence, in the majority of the patients, additional tricus-
pid valve surgery may be redundant. Therefore, patient selection
for concomitant tricuspid valve surgery should not be based sole-
ly on TR grade alone. Further studies are urgently needed to
tackle this clinical dilemma in the era of durable mechanical cir-
culatory support.
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